<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730860</url>
  </required_header>
  <id_info>
    <org_study_id>SWHB002</org_study_id>
    <nct_id>NCT00730860</nct_id>
  </id_info>
  <brief_title>Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE</brief_title>
  <official_title>Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization——a Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Science, Technology and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A RCT was conducted to elucidate whether the treatment outcome of HCC could be improved by
      RFA associated with postoperative TACE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized study was conducted to elucidate whether the outcome of hepatocellular carcinoma
      could be improved by radiofrequency ablation associated with postoperative transhepatic
      arterial chemoembolization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cancer of Liver</condition>
  <arm_group>
    <arm_group_label>RFA+TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment of hepatocellular carcinoma by radiofrequency ablation only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation associated with TACE</intervention_name>
    <description>treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization</description>
    <arm_group_label>RFA+TACE</arm_group_label>
    <other_name>Group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation only</intervention_name>
    <description>treatment of hepatocellular carcinoma by radiofrequency ablation only</description>
    <arm_group_label>RFA only</arm_group_label>
    <other_name>Group B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with hepatocellular,confirmed by pathological examination

          -  patients with a live function test showed Child A or B

          -  Indocyanine green test showed less than 30％ after 15min,and the patients showed a
             tolerance of RFA and TACE

          -  Tumor stage is early period(according to Milan Standard),that is,the diameter of
             single node should be less than 5cm；the node of tumor should be less than 3 and the
             diameter less than 3cm.

          -  without metastasis in lymphnode or other organs

          -  written consent inform assigned

        Exclusion Criteria:

          -  preoperative examination showed malignant thrombosis in the first class branch of
             portal vein or hepatic vein or vena cava

          -  metastatic cancer of liver

          -  patients with a poor tolerance of RFA and TACE

          -  patients received other therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ma Kuansheng, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Institute of hepatobiliary surgery,Southwest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Xiaobin, M.D</last_name>
    <phone>+86-23-68765297</phone>
    <email>fengxiaobin200708@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of hepatobiliary surgery</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Kuansheng, Ph.D</last_name>
      <phone>86-23-68765297</phone>
      <email>xiaobinf@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Feng Xiaobin, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>feng xiaobin</investigator_full_name>
    <investigator_title>Dr Xiaobin Feng</investigator_title>
  </responsible_party>
  <keyword>radiofrequency ablation</keyword>
  <keyword>Cancer of Liver</keyword>
  <keyword>postoperative</keyword>
  <keyword>transhepatic arterial chemoembolization</keyword>
  <keyword>prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

